Abstract:Highlights • Synthetic lethality offers a promising means for expanding drug target space for cancer treatment. • We developed a knowledge and data dual-driven AI framework for synthetic lethality prediction (KDDSL). • KDDSL is a "visible" AI framework that integrates domain knowledge to explore synthetic lethality and its implications in cancer treatment. This "visible" framework enhances the trust between biologists and AI. • KDDSL can help in identifying SL interactions and guiding the design of synergistic anti-cancer combination therapies. • By applying KDDSL, we identified the combination of MDM2 and CDK9 inhibitors, which demonstrated significant anticancer effects in vitro and in vivo. Introduction Synthetic lethality (SL) provides an opportunity to leverage different genetic interactions when designing synergistic combination therapies. To further explore SL-based combination therapies for cancer treatment, it is important to identify and mechanistically characterize more SL interactions. Artificial intelligence (AI) methods have recently been proposed for SL prediction, but the results of these models are often not interpretable such that deriving the underlying mechanism can be challenging. Objectives This study aims to develop an interpretable AI framework for SL prediction and subsequently utilize it to design SL-based synergistic combination therapies. Methods We propose a knowledge and data dual-driven AI framework for SL prediction (KDDSL). Specifically, we use gene knowledge related to the SL mechanism to guide the construction of the model and develop a method to identify the most relevant gene knowledge for the predicted results. Results Experimental and literature-based validation confirmed a good balance between predictive and interpretable ability when using KDDSL. Moreover, we demonstrated that KDDSL could help to discover promising drug combinations and clarify associated biological processes, such as the combination of MDM2 and CDK9 inhibitors, which exhibited significant anti-cancer effects in vitro and in vivo . Conclusion These data underscore the potential of KDDSL to guide SL-based combination therapy design. There is a need for biomedicine-focused AI strategies to combine rational biological knowledge with developed models. Graphical abstract KDDSL open the black box of neural network to achieve interpretable prediction of SL (The two shields represent two SL genes). This can help us utilize SL to kill cancer cell. Download : Download high-res image (92KB) Download : Download full-size image

Mapping the landscape of synthetic lethal interactions in liver cancer

Synthetic Lethality: a Promising Therapeutic Strategy for Hepatocellular Carcinoma.

Link Synthetic Lethality to Drug Sensitivity of Cancer Cells.

The tumor therapy landscape of synthetic lethality

Ranking Novel Cancer Driving Synthetic Lethal Gene Pairs Using TCGA Data

SLAYER: A Computational Framework for Identifying Synthetic Lethal Interactions through Integrated Analysis of Cancer Dependencies

Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network

Computational methods, databases and tools for synthetic lethality prediction

SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment

Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy

Systematic Analysis of Cancer-Specific Synthetic Lethal Interactions Provides Insight into Personalized Anticancer Therapy.

SLOAD: a comprehensive database of cancer-specific synthetic lethal interactions for precision cancer therapy via multi-omics analysis

CSSLdb: Discovery of cancer-specific synthetic lethal interactions based on machine learning and statistic inference

Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis

Abstract 5813: AI-driven identification and validation of novel synthetic lethal gene pairs through deep mining of cancer dependency data

An interpretable artificial intelligence framework for designing synthetic lethality-based anti-cancer combination therapies

Exploring synthetic lethal network for the precision treatment of clear cell renal cell carcinoma

Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer

Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates.

Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens